Purchase Order HHSN272201700730P

The Defense Health Agency awarded a $11.6 million delivery order against its Medical Product Research and Development master IDIQ contract to PPD Development LP. This cost-plus-fixed-fee order is to provide clinical monitoring services for a Phase 2B proof of concept study being conducted in South Africa. The study aims to develop an HIV vaccine that meets the requirements of the U.S. Military. Performance will take place in South Africa over a five year period concluding in October 2022. No set...

This is a delivery order issued against the Homeland Defense and Security Technical Area Tasks (HD TATs) indefinite-delivery indefinite-quantity (IDIQ) contract, which is held by the U.S. Air Force Materiel Command. The $12,284,540.00 contract was awarded to Battelle Memorial Institute, a non-profit research and development organization, to support the Joint Vaccine Acquisitions Program's advanced filovirus vaccine development and continued medical countermeasures research. The contract involves...

The Department of the Army Medical Command awarded a $359,747 firm-fixed-price delivery order contract to PPD Development LP, a global contract research organization, for HIV vaccine market research. The contract is not set aside and is part of the Medical Product Research and Development Indefinite Delivery Contract (IDC) vehicle. PPD has extensive experience as a prime contractor and subcontractor providing clinical trial, research, regulatory, and other support services to federal agencies...

This federal contract award is for Protocol Development (base) and Protocol Implementation (options 1-6) services related to a Phase II clinical trial (Protocol 14-0112) to evaluate the safety, reactogenicity, and immunogenicity of the M-001 influenza A/H7N9 vaccine in healthy volunteers. The award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, under the Vaccine and Treatment Evaluation Units...

The Department of the Army Medical Command awarded a $18 million Other Transaction Agreement to Janssen Vaccines & Prevention B.V., doing business as JPC, to perform Phase 3 of the HPX3002/HVTN 706/MOSAICO pivotal efficacy study. The study will be conducted in the Netherlands to evaluate Janssen's investigational vaccine for the prevention of HIV-1 infection. As the Army's medical research agency, the Medical Command supports the development and testing of vaccines and therapies through...

This is a Cost Plus Fixed Fee delivery order contract awarded by the Defense Health Agency to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp, to perform research and development in support of the U.S. Army Medical Materiel Development Activity (USAMMDA). The contract is for a Phase I, multi-center, randomized, double-blind, placebo-controlled study to assess the long-term ophthalmic safety of tafenoquine versus placebo. The potential value of the contract is $24,238,920.68,...

This is a delivery order awarded to Technical Resources International, Inc. (TRI) by the Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) for the CLINICAL MONITORING INITIATIVE (CMI) VACCINE RESEARCH CENTER (VRC) 325 MOSAIC QUADRIVALENT INFLUENZA VACCINE project. The order is part of the VRC Clinical Monitoring Initiative 2017-2024 indefinite delivery/indefinite quantity (IDIQ) contract and has a potential...

This is a modification to an existing delivery order contract (#HHSO10020160004I, Task Order 75A50119F33009) awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to GlaxoSmithKline, LLC. The purpose of the modification is to extend the period of performance from August 28, 2019 to February 28, 2024, to a new end date of April 30, 2024. The contract is for an AS03B-H7N9 vaccine clinical study, with a total ceiling value of $18,161,554.28. The contract is a firm...

The International AIDS Vaccine Initiative Inc. (IAVI) was awarded a $166.9 million firm fixed-price definitive contract by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to advance the development of monovalent vaccines for the prevention of Marburg virus (MARV) and Sudan ebolavirus (SUDV) disease. The vaccines are based on recombinant expression of filovirus glycoproteins and represent critical medical countermeasures against emerging infectious disease threats....

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $116,384 delivery order contract to The Johns Hopkins University. This follows a previous Phase I clinical study of a recombinant live attenuated tetravalent dengue virus vaccine. The Johns Hopkins University will conduct long-term follow up of previously enrolled subjects to further evaluate safety and immunogenicity. Two subcontracts were awarded in support of this work, including $117K to the...